RT Journal Article
SR Electronic
T1 18F-FDG PET parameters of the primary tumor have the prognostic value in patients with operable breast cancer without neoadjuvant chemotherapy.
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1494
OP 1494
VO 57
IS supplement 2
A1 Cha, Jongtae
A1 Kim, Soyoung
A1 HWANG, SANG HYUN
A1 Lee, Narae
A1 Cho, Arthur
A1 Kang, Won Jun
A1 Yun, Mijin
YR 2016
UL http://jnm.snmjournals.org/content/57/supplement_2/1494.abstract
AB 1494Objectives The purpose of this study was to investigate whether 18F-FDG PET parameters of the primary tumor have the prognostic value in patients with operable breast cancer without neoadjuvant chemotherapy.Methods From January 2008 to December 2012, patients underwent 18F-FDG PET/CT for initial staging and surgery without neoadjuvant chemotherapy were enrolled this study, retrospectively. Total 327 early breast cancer patients pathologically proven breast cancer was included. Disease-free survival (DFS) was defined as the time from the first day of cancer treatment to the day of cancer recurrence. A receiver operating characteristic(ROC) curve analysis was used to determine the optimal cut-off value of the maximum standardized uptake value(SUVmax). Cox proportional hazard model was used with age, tumor size, presence of lymph node metastasis, tumor grade, lymphovascular invasion, presence of adjuvant therapy, luminal group, and PET parameter (SUVmax) to predict recurrence.Results Median follow up duration was 46.39+-13.39 months. The incidence of recurrence was 17/329. (5.17%) During the follow up, 3 (17.6%) patients had locoregional recurrence and 14 (82.4%) patients had distant metastasis. On univariate analysis, a primary SUVmax(cutoff) and luminal group were predictive of recurrence. However, on multivariate analysis, only the primary SUVmax(cutoff) were significantly associated with recurrence. (odd ratio 5.808; 65% CI 1.157, 29.149; p = 0.033)Conclusions In conclusion, we demonstrated that high SUVmax in a primary site was the only independent prognostic factor for operable breast cancer. In early breast cancer, the patients whose tumor shown high SUVmax on pretreatment PET/CT may need for more aggressive surveillance.